Analyst Activity – Citigroup Inc. Reiterates Buy on Reata Pharmaceuticals (NASDAQ:RETA)

ME Staff
-
0

Analyst Ratings For Reata Pharmaceuticals (NASDAQ:RETA)

Today, Citigroup Inc. reiterated its Buy rating on Reata Pharmaceuticals (NASDAQ:RETA) with a price target of $87.00.

There are 6 buy ratings on the stock.

The current consensus rating on Reata Pharmaceuticals (NASDAQ:RETA) is Buy (Score: 3.00) with a consensus target price of $56.60 per share, a potential 59.57% upside.

Some recent analyst ratings include

  • 7/25/2017-Citigroup Inc. Reiterated Rating of Buy.
  • 4/13/2017-Ladenburg Thalmann Financial Services initiated coverage with a Buy rating.
  • 2/22/2017-Stifel Nicolaus initiated coverage with a Buy rating.
  • 1/24/2017-Robert W. Baird initiated coverage with a Outperform rating.
  • 12/1/2016-Cowen and Company Reiterated Rating of Buy.

Recent Insider Trading Activity For Reata Pharmaceuticals (NASDAQ:RETA)
Reata Pharmaceuticals (NASDAQ:RETA) has insider ownership of 62.40% and institutional ownership of 41.83%.

  • On 6/14/2017 A/S Novo, Major Shareholder, sold 61,000 with an average share price of $25.11 per share and the total transaction amounting to $1,531,710.00. View SEC Filing
  • On 6/13/2017 A/S Novo, Major Shareholder, sold 11,389 with an average share price of $25.47 per share and the total transaction amounting to $290,077.83. View SEC Filing
  • On 6/12/2017 A/S Novo, Major Shareholder, sold 222,503 with an average share price of $25.71 per share and the total transaction amounting to $5,720,552.13. View SEC Filing
  • On 6/7/2017 A/S Novo, Major Shareholder, sold 89,497 with an average share price of $28.24 per share and the total transaction amounting to $2,527,395.28. View SEC Filing
  • On 6/6/2017 A/S Novo, Major Shareholder, sold 64,170 with an average share price of $28.09 per share and the total transaction amounting to $1,802,535.30. View SEC Filing
  • On 6/5/2017 A/S Novo, Major Shareholder, sold 23,327 with an average share price of $28.67 per share and the total transaction amounting to $668,785.09. View SEC Filing
  • On 3/28/2017 Abbvie Inc., Major Shareholder, sold 450,000 with an average share price of $22.50 per share and the total transaction amounting to $10,125,000.00. View SEC Filing

Recent Trading Activity for Reata Pharmaceuticals (NASDAQ:RETA)
Shares of Reata Pharmaceuticals closed the previous trading session at 35.35 down -0.12 -0.34% with 1,103,256 shares trading hands.